B cells maintain the homeostasis of splenic marginal zone antigen-presenting cells to promote the antiviral CD8<sup>+</sup> T-cell response. [PDF]
Liu X +28 more
europepmc +1 more source
Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects
Bacterial outer membrane vesicles (OMVs) have emerged as versatile platforms for cancer vaccine development owing to their intrinsic immunostimulatory properties and high engineering flexibility. This review summarizes OMV biology, immune mechanisms, and engineering strategies that enhance vaccine efficacy, discusses key translational challenges, and ...
Jiabeini Zhang +9 more
wiley +1 more source
How the Immune System Recognizes the Myriad of Antigens: Diversity of MHC (HLA) and TCR Molecules. [PDF]
Akiba H.
europepmc +1 more source
Living Hydrogels: Harnessing Microorganism–Material Synergy for Next‐Generation Therapeutics
. ABSTRACT Microorganism‐based therapies, particularly those utilizing probiotics, have emerged as a powerful biomedical strategy owing to their inherent living functionalities. These living systems can dynamically interact with host environments and self‐regulate their activity, offering superior adaptability, prolonged functionality, and ...
Shuifang Mao +3 more
wiley +1 more source
Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity. [PDF]
Wang H +4 more
europepmc +1 more source
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin +12 more
wiley +1 more source
Cold atmospheric plasma-engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity. [PDF]
Li S +20 more
europepmc +1 more source
Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen +13 more
wiley +1 more source

